Stockscreener 앱 받기
13.56
9.40%
1.165
시간 외 거래:
13.56
전일 마감가:
$12.39
열려 있는:
$12.36
하루 거래량:
227.24K
Relative Volume:
1.18
시가총액:
$295.25M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+35.87%
1개월 성능:
+29.14%
6개월 성능:
+13.47%
1년 성능:
+0.00%
1일 변동 폭
$12.32
$13.77
1주일 범위
$9.18
$13.77
52주 변동 폭
$4.88
$19.58
Aardvark Therapeutics Inc Stock (AARD) Company Profile
명칭
Aardvark Therapeutics Inc
전화
(858) 225-7696
주소
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
AARD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
13.56 | 269.99M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-03 | 개시 | Raymond James | Strong Buy |
| 2025-11-07 | 개시 | BTIG Research | Buy |
| 2025-09-29 | 개시 | Stifel | Buy |
| 2025-06-30 | 개시 | H.C. Wainwright | Buy |
| 2025-03-10 | 개시 | BofA Securities | Buy |
| 2025-03-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-10 | 개시 | Morgan Stanley | Overweight |
| 2025-03-10 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Aardvark Therapeutics Inc 주식(AARD)의 최신 뉴스
Will Aardvark Therapeutics Inc. stock benefit from commodity pricesMarket Growth Report & Daily Market Momentum Tracking - Newser
Raymond James Financial Begins Coverage on Aardvark Therapeutics (NASDAQ:AARD) - MarketBeat
Individual investors among Aardvark Therapeutics, Inc.'s (NASDAQ:AARD) largest shareholders, saw gain in holdings value after stock jumped 23% last week - simplywall.st
AARD: Phase 3 Prader-Willi data expected Q3 2026; obesity program readout by end of next year - TradingView
Aardvark Therapeutics initiated with a Strong Buy at Raymond James - TipRanks
Raymond James initiates coverage on Aardvark Therapeutics stock with Strong Buy - Investing.com UK
Aardvark Therapeutics Hosts Investor Webinar on Drug Programs - MSN
Analysts Set Aardvark Therapeutics, Inc. (NASDAQ:AARD) PT at $30.63 - Defense World
What risks investors should watch in Aardvark Therapeutics Inc. stockEarnings Trend Report & Real-Time Chart Breakout Alerts - BỘ NỘI VỤ
Aardvark Therapeutics to Present at Upcoming Investor Conferences in December - The Manila Times
Why Aardvark Therapeutics Inc. stock is seen as undervalued2025 Big Picture & Fast Gain Swing Alerts - newser.com
Will Aardvark Therapeutics Inc. stock attract ESG investorsJuly 2025 Short Interest & Stepwise Entry/Exit Trade Alerts - newser.com
From HERO To POWER: AARD Charts Bold Course In Obesity And Rare Disease Trials - RTTNews
Real time social sentiment graph for Aardvark Therapeutics Inc. - newser.com
Aardvark Therapeutics Reports Q3 2025 Financial Results - TipRanks
Is Aardvark Therapeutics Inc. forming a reversal patternGold Moves & Reliable Entry Point Alerts - newser.com
RBC Capital Maintains Aardvark Therapeutics (AARD) Outperform Recommendation - Nasdaq
Cantor Fitzgerald reiterates Overweight rating on Aardvark Therapeutics stock By Investing.com - Investing.com Nigeria
Stifel reiterates Buy rating on Aardvark Therapeutics stock, maintains $24 target - Investing.com Nigeria
Cantor Fitzgerald reiterates Overweight rating on Aardvark Therapeutics stock - Investing.com
Can Aardvark Therapeutics Inc. stock deliver sustainable ROEMarket Performance Report & Verified Momentum Stock Watchlist - Fundação Cultural do Pará
Aardvark Therapeutics stock price target lowered to $18 at RBC Capital By Investing.com - Investing.com South Africa
Aardvark Therapeutics stock price target lowered to $18 at RBC Capital - Investing.com Nigeria
Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates - The Manila Times
Aardvark Therapeutics, Inc. SEC 10-Q Report - TradingView
Aardvark (Nasdaq: AARD) aligns with FDA to lower HERO trial age to 10, runway into 2027 - Stock Titan
Is Aardvark Therapeutics Inc. building a consolidation baseJuly 2025 Sentiment & High Accuracy Buy Signal Tips - newser.com
Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Aardvark Therapeutics (NASDAQ: AARD) grants 4,881-share inducement option at $10.44 - Stock Titan
Aardvark Therapeutics, Inc.: Undervalued Potential in the Obesity Treatment Market with Promising Pipeline - TipRanks
Is Aardvark Therapeutics Inc. forming a bottoming basePortfolio Gains Summary & Free Expert Verified Stock Movement Alerts - newser.com
Aardvark Therapeutics Showcases Obesity Research at ObesityWeek - MSN
Is Aardvark Therapeutics Inc. stock attractive for income investorsWeekly Risk Summary & Safe Capital Growth Stock Tips - newser.com
Aardvark Therapeutics Inc (AARD) 재무 분석
Aardvark Therapeutics Inc (AARD)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Aardvark Therapeutics Inc 주식 (AARD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Jones Bryan | Chief Operating Officer |
Oct 15 '25 |
Option Exercise |
4.24 |
1,250 |
5,300 |
1,250 |
| Lee Tien-Li | Chief Executive Officer |
Sep 15 '25 |
Buy |
9.66 |
10,000 |
96,624 |
1,543,384 |
1.44%
0.91%
자본화:
|
볼륨(24시간):